12537 Once Daily Oral Atumelnant (CRN04894) Induces Rapid And Profound Reductions Of Androstenedione And 17-Hydroxyprogesterone In Participants With Classical Congenital Adrenal Hyperplasia: Initial Results From A 12-Week, Phase 2, Open-Label StudyRichard J. Auchus, Umasuthan Srirangalingam, Yang Wu et al.|Journal of the Endocrine Society|2024Cited by 8
SUN-438 Rapid And Sustained Reduction Of 11-oxygenated Androgens In Adults With Classic Congenital Adrenal Hyperplasia Following Once-daily Oral Atumelnant (CRN04894): Results From A 12-week, Phase 2, Open-label StudyNicole Reisch, Deborah P. Merke, Lise Kjems et al.|Journal of the Endocrine Society|2025Cited by 1
SAT-452 Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label StudyTânia A.S.S. Bachega, Umasuthan Srirangalingam, Jamie Marko et al.|Journal of the Endocrine Society|2025Cited by 1